Index by author

This is a retrospective analysis of 484 patients in a prospectively collected stroke data base. The inclusion criteria were anterior circulation ischemic stroke treated with mechanical thrombectomy at a single institution between September 2010 and October 2015 with an NIHSS score of ≤8. The purpose was to assess the clinical and interventional data in patients treated with mechanical thrombectomy in case of ischemic stroke with mild-to-moderate symptoms (n = 33). Recanalization (TICI 2b–3) was achieved in 26 (78.7%) patients. Two cases of symptomatic intracranial hemorrhage occurred. Favorable (mRS 0–2) and moderate (mRS 0–3) clinical 90-day outcome was achieved in 63.6% and 90.9% of patients, respectively. The authors conclude that the clinical outcome of patients undergoing mechanical thrombectomy for acute ischemic mild stroke due to large-vessel occlusion is predominately favorable, even in a prolonged time window.

Twenty-four patients with recurrent high-grade gliomas were scanned before and during bevacizumab treatment with standard and delayed-contrast MRI. The mean change in lesion volumes of responders (overall survival, >1 year) and nonresponders (overall survival, <1 year) was evaluated. Treatment-response-assessment maps (TRAMs) were calculated by subtracting conventional T1WI (acquired a few minutes postcontrast) from delayed T1WI (acquired with a delay of >1 hour postcontrast). These maps depict the spatial distribution of contrast accumulation and clearance. At progression, the increase in lesion volumes in delayed-contrast MR imaging was 37.5% higher than the increase in conventional T1WI. The authors conclude that the benefit of standard and delayed-contrast MRI for assessing and predicting the response to bevacizumab was demonstrated and that the increased sensitivity of delayed-contrast MRI reflects its potential contribution to the management of bevacizumab-treated patients with recurrent HGG.